^
    23h
    PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    2d
    Vorinostat in Treating Patients With Metastatic Melanoma of the Eye (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Zolinza (vorinostat)
    3d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    3d
    ‌A Phase II, Two-Stage Study Evaluating the Efficacy of Entinostat in Combined with Fulvestrant in Locally Advanced or Metastatic Breast Cancer with Recurrence or Progression after CDK4/6 Inhibitor plus Endocrine Therapy (ChiCTR2500114131)
    P=N/A, N=50, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • Jingzhuda (entinostat)
    3d
    A prospective, multicenter, cocohort controlled clinical trial on the efficacy and safety of chidamide in maintenance treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (ChiCTR2500112540)
    P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    3d
    A phase III clinical study of Purinostat Mesylate for Injection in patients with diffuse large B-cell lymphoma (ChiCTR2500114877)
    P3, N=390, Recruiting, West China Hospital of Sichuan University/Ruijin Hospital of Shanghai Jiao Tong University School of Medicine; Chengdu Zenitar Biomedical Technology C
    New P3 trial
    |
    Xpovio (selinexor) • purinostat
    3d
    Clinical Study of Chidamide Combined with Azacitidine for Maintenance Therapy in Adult Acute T Lymphoblastic Leukemia/ T Lymphoblastic Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation (ChiCTR2500114134)
    P2, N=17, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    azacitidine • Epidaza (chidamide)
    4d
    Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
    P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025
    Trial completion • Trial completion date
    |
    TNFRSF8 positive
    |
    lenalidomide • dexamethasone • Istodax (romidepsin) • Onureg (azacitidine oral)
    5d
    Discovery of Tertiary Benzenesulfonanilide Chemotypes as HDAC Inhibitors via Multistrategy In Silico and Biological Evaluation for Colon Cancer Therapy. (PubMed, J Med Chem)
    Mechanistically, HIT211504993 inhibits Myc-driven tumorigenesis by promoting nucleocytoplasmic acetylation and modulating p53, cell-cycle, and Wnt/β-catenin signaling. The investigation of antitumor activity and its mechanism of action provides a theoretical basis for the development of the next-generation benzenesulfonanilide HDAC inhibitors.
    Journal
    |
    HDAC2 (Histone deacetylase 2) • HDAC4 (Histone Deacetylase 4)
    |
    Zolinza (vorinostat)
    6d
    A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
    P2, N=36, Recruiting, China Medical University, China
    New P2 trial
    |
    carboplatin • etoposide IV • Epidaza (chidamide)
    6d
    VALOR: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Zolinza (vorinostat) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • lutetium zadavotide guraxetan (PNT2002)
    7d
    Nucleosome Clustering as a Biomarker and Mechanistic Switch for Reprogramming Cells. (PubMed, Cells)
    Consistently, pharmacological agents-Trichostatin A as a histone deacetylase inhibitor and chaetocin as a histone methyltransferase inhibitor-induced nucleosome scattering and converted U2OS cells into iTS cells, whose conditioned media exerted tumor-suppressive effects. Our findings highlight nucleosome clustering as a key epigenetic feature responsive to both biophysical and chemical cues, underscoring its role in microscale chromatin remodeling and reprogramming of the tumor microenvironment.
    Journal
    |
    KDM3A (Lysine Demethylase 3A)
    |
    trichostatin A (VTR-297)